Robotic-assisted prostate cancer surgery drives up costs

May 23, 2012, University of Pittsburgh Schools of the Health Sciences

In one of the most comprehensive analyses to date of the cost of robotic-assisted, laparoscopic surgery for prostate cancer, researchers at UPMC found that this now-dominant surgical approach is significantly more costly than standard open surgery, despite little scientific evidence of long-term improved patient outcomes. The results of the study are available online and will appear in the July issue of the journal Urology.

In one of the first studies based on actual direct and indirect costs at a single institution—rather than computer models that evaluate theoretical costs—the researchers found that the mean total cost per case of robotic-assisted laparoscopic radical prostatectomy (RARP) exceeded by 62 percent the cost of open radical retropubic prostatectomy (RRP). There was no significant difference in the mean length of stay for patients undergoing RARP vs. RRP, 1.2 and 1.4 days, respectively.

Since payment to the hospital was nearly equivalent for both types of procedures, the hospital lost $4,013 on average for each RARP case, while the payments exceeded costs by $1,325 for the standard open approach. Most of the cost difference, researchers found, was attributable to the robotic equipment and supplies.

"Nearly 240,000 new cases of prostate cancer are diagnosed annually, and radical prostatectomy is the most common treatment," said Joel B. Nelson, M.D., senior author of the study and chairman of the Department of Urology at UPMC and the University of Pittsburgh School of Medicine. "The value of that care for patients is of particular concern to a nation struggling to control health care costs while improving outcomes." During the past decade, he noted, RARP has become the dominant surgical approach in the treatment of prostate cancer, with a surgeon controlling a robot's arms remotely to remove cancerous organs through small incisions in the patient's abdomen. Yet there is limited data to show that this technological innovation has produced better long-term patient results. "It is reasonable to question whether the increased costs of this robotic-assisted approach are justified," said Dr. Nelson, who is also co-director of the University of Pittsburgh Cancer Institute's Program.

For their cost analysis, the researchers looked at the treatment of 473 consecutive patients from July 2009 to October 2010 at UPMC Shadyside hospital. Four urologic oncologists with considerable experience in RARP and RRP operated on these patients, using RARP for 115 and RRP for 358.

The overall cost per case for RARP exceeded the cost for RRP by almost $5,300. The major contributors to the cost gap were greater operating room supply costs and indirect costs associated with the purchase and maintenance of the robotic equipment. Operating room supply costs were almost seven times greater for RARP, while ancillary, cardiology, imaging, administrative, laboratory and pharmacy costs were not significantly different between the two approaches.

Several previous studies also have demonstrated a cost advantage for the standard open surgical approach. However, those studies sometimes excluded certain or involved hospitals with lower surgical volumes or surgeons who were less experienced with the robotic-assisted technology, potentially skewing the cost per case.

Dr. Nelson noted that randomized clinical trials—the gold standard in scientific research—comparing RRP and RARP are lacking. But a recent review of 37 comparative prostatectomy studies found no superiority for one approach vs. the other in terms of functional (such as post-operative continence and potency) and oncologic outcomes for patients.

"While further studies are needed to compare the long-term outcomes of RRP vs. RARP, our study suggests that our society may be paying too high a price for what has been widely perceived as a medical advance," said Dr. Nelson.

Explore further: Researchers find anatomic differences after robotic-assisted radical prostatectomy

Related Stories

Researchers find anatomic differences after robotic-assisted radical prostatectomy

April 11, 2011
Researchers from Boston University School of Medicine (BUSM) have concluded that the anatomy of the pelvis following robotic-assisted radical prostatectomy

Fewer complications, better outcomes with robot-assisted prostate cancer surgery

April 24, 2012
Robot-assisted surgery is now both more common and far more successful than radical "open" surgery to treat prostate cancer in the United States, according to a new Henry Ford Hospital study published in the current issue ...

Recommended for you

Researchers identify new treatment target for melanoma

January 16, 2018
Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a new therapeutic target for the treatment of melanoma. For decades, research has associated female sex and a history of previous ...

More evidence of link between severe gum disease and cancer risk

January 16, 2018
Data collected during a long-term health study provides additional evidence for a link between increased risk of cancer in individuals with advanced gum disease, according to a new collaborative study led by epidemiologists ...

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

New immunotherapy approach boosts body's ability to destroy cancer cells

January 12, 2018
Few cancer treatments are generating more excitement these days than immunotherapy—drugs based on the principle that the immune system can be harnessed to detect and kill cancer cells, much in the same way that it goes ...

Cancer's gene-determined 'immune landscape' dictates progression of prostate tumors

January 12, 2018
The field of immunotherapy - the harnessing of patients' own immune systems to fend off cancer - is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.